Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Development of libiguin as medicament for erectile dysfunction and premature ejaculation

Reference number
Coordinator Dicot AB - Dicot AB c/o Uppsala Universitet Holding
Funding from Vinnova SEK 300 000
Project duration March 2017 - November 2017
Status Completed
Venture Innovative Startups

Purpose and goal

The purpose of the project in its entirety is to develop an industrial process for the manufacture of libiguin API to enable preclinical toxicity tests and clinical trials to finally register libiguin as a drug and ensure that the libiguin API can be manufactured in sufficient quantities for the world markets.

Expected results and effects

Phase 1 of the project included prospecting raw-materials and development of extraction and purification methods for a precursor in the synthesis of libiguin. The prospecting has been successful; sources with good availability have been identified and one ton of raw-materials have already been acquired. An extraction and purification method has been developed and 60 grams of the precursor has already been obtained.

Planned approach and implementation

Prospecting has been carried out in cooperation with consultants. Extraction and purification methods have been developed in cooperation with CRO. The project has been completed in accordance with the project plans, and much faster than originally thought. One ton raw-materials have been collected and delivered to Sweden. Overall, Vinnova´s project funds have significantly reduced the risk of the project by ensuring that we now have sufficient raw-materials for the project´s continuation.

External links

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 4 February 2019

Reference number 2017-00375

Page statistics